TGFB1 and cardiac hypertrophy: We propose that ICG001 may control pathological cardiac hypertrophy and fibrosis via KLF5, immune activation, and the Wnt/β-catenin signaling pathway by connecting with TGF-β as a mediator (Fig. 6).